Ventyx Biosciences, Inc. (VTYX): Price and Financial Metrics

Ventyx Biosciences, Inc. (VTYX): $4.60

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add VTYX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#310 of 360

in industry

VTYX Price/Volume Stats

Current price $4.60 52-week high $40.58
Prev. close $4.60 52-week low $1.87
Day low $4.50 Volume 674,100
Day high $4.68 Avg. volume 4,004,947
50-day MA $5.63 Dividend yield N/A
200-day MA $16.01 Market Cap 324.30M

VTYX Stock Price Chart Interactive Chart >


Ventyx Biosciences, Inc. (VTYX) Company Bio


Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.


VTYX Latest News Stream


Event/Time News Detail
Loading, please wait...

VTYX Latest Social Stream


Loading social stream, please wait...

View Full VTYX Social Stream

Latest VTYX News From Around the Web

Below are the latest news stories about VENTYX BIOSCIENCES INC that investors may wish to consider to help them evaluate VTYX as an investment opportunity.

Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference

SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the upcoming 35th Annual Piper Sandler Healthcare Conference. Event: 35th Annual Piper Sandler Healthcare ConferenceLocation: New York, NYDate: Tuesday, November 28, 202

Yahoo | November 21, 2023

Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference

SAN DIEGO, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the upcoming Jefferies London Healthcare Conference. Event: Jefferies London Healthcare ConferenceLocation: London, United KingdomDate: Thursday, November 16, 2023Time:

Yahoo | November 10, 2023

Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress

Ventyx to provide updates across clinical-stage portfolio in the first quarter of 2024 Cash, cash equivalents and marketable securities of $300.8 million as of September 30, 2023 SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced financial results for the third qu

Yahoo | November 9, 2023

Down -86.57% in 4 Weeks, Here's Why Ventyx Biosciences, Inc. (VTYX) Looks Ripe for a Turnaround

Ventyx Biosciences, Inc. (VTYX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | November 9, 2023

PTON Stock Slumps as Deutsche Bank Downgrades Peloton

Peloton stock is taking a beating on Tuesday after shares of PTON were downgraded and saw their price target reduced by Deutsche Bank.

William White on InvestorPlace | November 7, 2023

Read More 'VTYX' Stories Here

VTYX Price Returns

1-mo -45.30%
3-mo 106.28%
6-mo -75.07%
1-year -84.99%
3-year N/A
5-year N/A
YTD 86.23%
2023 -92.47%
2022 65.11%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!